Ken Griffin Kamada LTD Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$4.83 - $6.25 $9,660 - $12,500	-2,000 Reduced 90.91%	200 $1,000
Q2 2024 Aug 14, 2024	BUY	$4.78 - $5.75 $9,082 - $10,925	1,900 Added 633.33%	2,200 $10,000
Q1 2024 May 15, 2024	BUY	$5.58 - $6.42 $1,116 - $1,284	200 Added 200.0%	300 $1,000
Q4 2023 Feb 14, 2024	BUY	$4.14 - $6.22 $413 - $622	100 New	100 $0
Q2 2023 Aug 14, 2023	BUY	$4.48 - $5.53 $3,136 - $3,871	700 Added 233.33%	1,000 $5,000
Q1 2023 May 15, 2023	SELL	$4.12 - $5.25 $2,060 - $2,625	-500 Reduced 62.5%	300 $1,000
Q4 2022 Feb 14, 2023	BUY	$3.79 - $4.84 $3,032 - $3,872	800 New	800 $3,000

6.48M

200

Ticker KMDA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 44,800,500
Market Cap $264M
Description
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.